Medical Digest & Congress Report

Professor Sofie Brouwers explained at ESH 2024 that antihypertensive treatment for chronic coronary artery disease should be based on an ACE inhibitor and the evidence supporting this.

Video: https://medicaldigest.org/scientific-contents/interview:hypertension-and-cad-need-more-spcs-report-esh2024

Professor Michel Burnier shared his thoughts on why is adherence is a key factor in good hypertensive management at ESH 2024.

Video: https://medicaldigest.org/scientific-contents/interview:challenges-hypertension-adherence-treatment

Professor Thomas Hoffmann, Director of the Department of Otolaryngology and Head and Neck Surgery at the University of Ulm, raises awareness of the growing number of HPV-associated head and neck cancers in our interview. The right combination of treatment modalities - less and less invasive surgical procedures, increasingly precise radiotherapy options and systemic therapies, especially immunotherapies - can make a dramatic difference to disease outcomes, while the role of prophylactic HPV vaccination cannot be overemphasised.

Video: https://medicaldigest.org/scientific-contents/interview:hpv-associated-head-and-neck-cancers

Dr. Robert Sifrer, Director of the Department of Otolaryngology and Head and Neck Surgery at the University of Ljubljana, believes that the most important breakthrough in the treatment of head and neck cancer patients has been the recent development of immunotherapy, which is also helping patients with advanced stage cancer, and expects the importance of drug therapies to increase in the future. He was also asked about the problems of caring for patients with head and neck cancer in our interview at the International Danube Symposium on Otolaryngology.

Video: https://medicaldigest.org/scientific-contents/interview:breakthroughs-and-challenges-treatment-head-and-neck-cancer

Professor George D. Dangas chaired the Featured Clinical Research on Monday and shared his insights on the trials about acute coronary syndromes, atrial fibrillation related ablation procedures and aortic valve replacements.

- Fractional Flow Reserve-guided Complete Or Culprit-only PCI In Patients With ST-elevation Myocardial Infarction

- Intravascular Ultrasound-guided Versus Angiography-guided Percutaneous Coronary Intervention In Acute Coronary Syndromes: The Multicenter, Randomized, Blinded, Ivus-acs Trial

- A Multicenter Prospective Randomized Study Comparing The Incidence Of Periprocedural Cerebral Embolisms Caused By Catheter Ablation Of Atrial Fibrillation Between Cryoballoon And Radiofrequency Ablation

- Protein And Exercise To Reverse Frailty In Older Men And Women Undergoing Transcatheter Aortic Valve Replacement: The PERFORM-TAVR Trial

- Transseptal Versus Retrograde Aortic Ventricular Entry To Reduce Systemic Emboli (the TRAVERSE Trial)

Video: https://medicaldigest.org/scientific-contents/interview:featured-clinical-researches-acute-coronary-syndromes-atrial-fibrillation-related-ablation-procedures-and-aortic-valve-replacements

Professor Andrew M. Kates shared his insights on Late-Breaking Clinical Trials II, presented during at ACC.24:

- Zilebesiran In Combination With A Standard-of-care Antihypertensive In Patients With Inadequately Controlled Hypertension – Primary Results From The Phase 2 Kardia-2 Study

- Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

- Plozasiran (ARO-APOC3), An Investigational RNAi Therapeutic, Demonstrates Profound And Durable Reductions In APOC-3 And Triglycerides (TG) In Patients With Severe Hypertriglyceridemia (SHTG), SHASTA-2 Final Results

- Efficacy And Safety Of Olezarsen In Patients With Hypertriglyceridemia And High Cardiovascular Risk: Primary Results Of The BRIDGE-TIMI 73a Trial

- Effect Of Gamification, Financial Incentives Or Both Combined To Increase Physical Activity Among Patients With Elevated Risk For Major Adverse Cardiovascular Events. The Be Active Randomized Clinical Trial

Video: https://medicaldigest.org/scientific-contents/interview:late-breaking-clinical-trials-cholesterol-management-hypertension-and-exercise

Professor Athena Poppas shared his insights on the Late Breaking Clinical Trial sessions:

- Effect Of Edetate Disodium Based Chelation Infusions On Cardiovascular Events In Post-MI Patients With Diabetes: The TACT2 Trial

- Percutaneous Transvalvular Micro-axial Flow Pump In Infarct Related Cardiogenic Shock: Results Of The Danger-shock Trial

- A Selective Aldose Reductase Inhibitor (at-001) For The Treatment Of Diabetic Cardiomyopathy: Primary Results Of The Phase 3 Randomized Controlled Arise-hf Study

Video: https://medicaldigest.org/scientific-contents/interview:late-breaking-clinical-trial-acc

Professor Mikhail Kosiborod shared his insights onthe STEP-HFpEF and STEP-HFpEF DM randomised trials.

Discussed studies:

- Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

- Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

Video: https://medicaldigest.org/scientific-contents/interview:semaglutide-versus-placebo-people-obesity-related-heart-failure-preserved-ejection-fraction-step-hfpef-and-step-hfpef-dm-randomised-trials

ACC Immediate-Past President Edward T. A. Fry chaired the Late Breaking Clinical Trial V. and shared his insights on the trials:

- Coronary Sinus Reducer For The Treatment Of Refractory Angina: A Randomised, Placebo-controlled Trial (ORBITA-COSMIC)

- Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement In Patients At Low To Intermediate Risk: One Year Outcomes Of The Randomized DEDICATE-DZHK6 Trial

- Effect Of Alcohol-mediated Renal Denervation On Blood Pressure In The Presence Of Antihypertensive Drugs: 3-month Primary Results From The Target Bp I Randomized Trial

- Preventive PCI Or Medical Therapy Alone For Atherosclerotic Coronary Vulnerable Plaques

- Comparison Of Intravascular Ultrasound-guided Versus Angiography-guided Angioplasty For The Outcomes Of Drug-coated Balloon In The Treatment Of Femoropopliteal Artery Disease

Video: https://medicaldigest.org/scientific-contents/interview:late-breaking-clinical-trials-v

Professor Kathryn L. Berlacher shared his insights on Late-Breaking Clinical Trials IV, presented during at ACC.24:

- Outcomes After Technology Assisted Nonprescription Rosuvastatin Administration: The TACTiC Trial

- Preventing Cardiac Damage In Patients Treated For Breast Cancer And Lymphoma: A Phase 3 Randomized, Open Label, Blinded Endpoint, Superiority Trial Of Enalapril To Prevent Anthracycline-induced Cardiotoxicity (PROACT)

- Topical Tranexamic Acid To Reduce Seizures In Cardiac Surgery

- Efficacy And Safety Of Ninerafaxstat, A Novel Cardiac Mitotrope, In Patients With Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results Of IMPROVE-HCM

- A Selective Aldose Reductase Inhibitor (at-001) For The Treatment Of Diabetic Cardiomyopathy: Primary Results Of The Phase 3 Randomized Controlled Arise-hf Study

Video: https://medicaldigest.org/scientific-contents/interview:joint-american-college-cardiologyjournal-american-medical-association-late-breaking-clinical-trials-iv